Tag: real-time vs accelerated stability

Designing Bridging Studies Across US, EU, and ASEAN for Stability Data

In today’s global pharmaceutical landscape, companies often need to register the same product across multiple regulatory jurisdictions, such as the US (FDA), Europe (EMA), and Southeast Asia (ASEAN). Rather than repeating full stability studies in every region, firms can design scientifically justified bridging studies. This guide explains how to plan and execute effective bridging strategies…

Regional Guidelines: FDA, EMA, ASEAN, TGA, Regulatory Guidelines

Best Practices for Integrating ICH Q1A with Real-Time and Accelerated Stability Studies

The ICH Q1A(R2) guideline remains the cornerstone for stability testing of new drug substances and products. However, real-world challenges often arise in implementing its principles during both real-time and accelerated studies. This guide provides step-by-step best practices to help pharmaceutical professionals effectively integrate ICH Q1A with various stability approaches, ensuring both scientific robustness and regulatory…

ICH Stability Guidelines (Q1A–Q1E, Q8, Q9, etc.), Regulatory Guidelines

Real-Time vs Accelerated Stability Studies: Key Differences

Real-Time vs Accelerated Stability Studies: Key Differences Understanding the Differences Between Real-Time and Accelerated Stability Testing Stability testing ensures that a pharmaceutical product maintains its intended quality over time. This guide offers a comprehensive comparison between real-time and accelerated stability studies — two fundamental approaches used to determine drug product shelf life. Learn how each…

Real-Time and Accelerated Stability Studies, Stability Testing Types